LOG IN
SIGN UP
MARKET
MRTX
MRTX
Mirati Therapeut
NASDAQ
52.57
-1.69
-3.11%
After Hours: 51.00 -1.57 -2.99% 19:23 02/03 EST
OPEN
53.11
PREV CLOSE
54.26
HIGH
53.55
LOW
51.62
VOLUME
1.01M
TURNOVER
0
52 WEEK HIGH
124.81
52 WEEK LOW
32.96
MARKET CAP
3.03B
P/E (TTM)
-3.9281
1D
5D
1M
3M
1Y
5Y
B. Riley Securities Maintains Neutral on Mirati Therapeutics, Raises Price Target to $56
Benzinga · 01/23 13:13
B. Riley Raises Mirati Therapeutics' Price Target to $56 From $52, Keeps Neutral Rating
B. Riley Raises Mirati Therapeutics' Price Target to $56 From $52, Keeps Neutral Rating
MT Newswires · 01/23 08:05
FDA clears Mirati's investigational new drug application for its inhibitor MRTX1133
Seeking Alpha · 01/19 22:15
BRIEF-Mirati Announces IND Clearance By U.S. FDA
Reuters · 01/19 22:01
Mirati Therapeutics Says FDA Clears Investigational New Drug Application For Tumor Therapy MRTX1133
Mirati Therapeutics Says FDA Clears Investigational New Drug Application For Tumor Therapy MRTX1133
MT Newswires · 01/19 17:54
Insider Sell: Mirati Therapeutics
Insider Sell: Mirati Therapeutics
MT Newswires · 01/19 10:02
Tracking Baker Brothers Portfolio - Q3 2022 Update
Seeking Alpha · 01/06 07:38
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Benzinga · 12/27/2022 14:11
About MRTX
Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.
Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.